An alternative method to analyse the biomarker‐strategy design
暂无分享,去创建一个
[1] Daniel J Sargent,et al. Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All , 2009, Journal of biopharmaceutical statistics.
[2] Frank Yates,et al. The principles of orthogonality and confounding in replicated experiments. (With Seven Text-figures.) , 1933, The Journal of Agricultural Science.
[3] Daniel J Sargent,et al. Predictive biomarker validation in practice: lessons from real trials , 2010, Clinical trials.
[4] Richard Simon,et al. Development and Validation of Biomarker Classifiers for Treatment Selection. , 2008, Journal of statistical planning and inference.
[5] Daniel F. Hayes,et al. Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful? , 2004, Breast Cancer Research and Treatment.
[6] Daniel J Sargent,et al. Clinical trial designs for predictive marker validation in cancer treatment trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Antje Hoering,et al. Randomized Phase III Clinical Trial Designs for Targeted Agents , 2008, Clinical Cancer Research.
[8] D. Sargent,et al. Issues in clinical trial design for tumor marker studies. , 2002, Seminars in oncology.
[9] Les Irwig,et al. Sample Size and Power When Designing a Randomized Trial for the Estimation of Treatment, Selection, and Preference Effects , 2014, Medical decision making : an international journal of the Society for Medical Decision Making.
[10] Johny Verschakelen,et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial , 2013, Thorax.
[11] R. Simon. Clinical trials for predictive medicine , 2012, Statistics in medicine.
[12] K Y Young,et al. The efficiency of clinical trial designs for predictive biomarker validation , 2010, Clinical trials.
[13] Daniel J Sargent,et al. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Boris Freidlin,et al. Randomized clinical trials with biomarkers: design issues. , 2010, Journal of the National Cancer Institute.
[15] G. Rücker,et al. A two-stage trial design for testing treatment, self-selection and treatment preference effects. , 1989, Statistics in medicine.
[16] Richard Simon,et al. Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. , 2010, Personalized medicine.
[17] Weichung Joe Shih,et al. Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers , 2018, Statistics in medicine.
[18] S D Walter,et al. Optimal allocation of participants for the estimation of selection, preference and treatment effects in the two‐stage randomised trial design , 2012, Statistics in medicine.